Zuyderland Medical Centre Sittard-Geleen, Sittard-Geleen, Netherlands
Maarssen, Netherlands.
Eur J Hosp Pharm. 2021 Mar;28(2):e4. doi: 10.1136/ejhpharm-2020-002229. Epub 2020 Sep 12.
The large number of available medicines and devices makes it almost impossible to have sufficient knowledge of each individual medicine and device, especially for general practitioners. This may lead to suboptimal treatment, more exacerbations, hospitalisations and higher treatment costs. Reducing the number of medicines and devices, based on rational criteria, allows physicians and pharmacists to build experience with a more limited set of medicines and to standardise the inhalation instructions.
In this study inhalers are compared by means of the System of Objectified Judgement Analysis (SOJA) method. The following selection criteria were applied: uniformity in device, number of steps per inhalation, risk of errors, hygienic aspects, feedback mechanism, and risk of inhalation with an empty inhaler.
Substantial differences were seen in the overall scores, with the Ellipta device showing the highest score, followed by Diskus/Accuhaler, Genuair and Nexthaler. Several devices require more or less identical techniques, such Ellipta and Diskus/Accuhaler as well as Genuair and Novolizer. When patients use these devices in combination this increases their uniformity, because additional medicines become available for the devices: starting therapy with Diskus or Novolizer and follow-up with Ellipta or Genuair. The resistance of Respimat and Breezhaler is lower than that of other devices, which makes these devices suitable for patients who cannot generate sufficient inhalation flow.
A substantial reduction of inhalers, combined with optimal and standardised instructions, should improve the care of patients with chronic obstructive pulmonary disease.
大量的药物和设备使得几乎不可能对每一种药物和设备都有足够的了解,尤其是对于全科医生来说。这可能导致治疗效果不佳、更多的恶化、住院和更高的治疗费用。基于合理的标准减少药物和设备的数量,可以使医生和药剂师在更有限的药物集上积累经验,并使吸入说明标准化。
在这项研究中,采用客观判断分析系统(SOJA)方法对吸入器进行比较。应用了以下选择标准:装置的一致性、每次吸入的步骤数、错误风险、卫生方面、反馈机制以及吸入空吸入器的风险。
在总评分方面存在显著差异,Ellipta 装置得分最高,其次是 Diskus/Accuhaler、Genuair 和 Nexthaler。一些设备需要或多或少相同的技术,例如 Ellipta 和 Diskus/Accuhaler 以及 Genuair 和 Novolizer。当患者联合使用这些设备时,会增加它们的一致性,因为这些设备增加了更多的药物选择:从 Diskus 或 Novolizer 开始治疗,然后用 Ellipta 或 Genuair 进行后续治疗。Respimat 和 Breezhaler 的阻力比其他设备低,这使得这些设备适合那些无法产生足够吸入气流的患者。
大量减少吸入器,并结合最佳和标准化的说明,应改善慢性阻塞性肺疾病患者的护理。